This study intends to investigate how Inhibin subunit beta A (INHBA) promotes the progression of GC by activating the mitogen-activated protein kinase (MAPK) signaling pathway via targeting Integrin alpha-6 (ITGA6).<h4>Methods</h4>Quantitative reverse transcription-Polymerase Chain Reaction (qRT-PCR) and Immunohistochemistry (IHC) were utilised to validate the expression levels of INHBA in GC, which were subsequently correlated with the clinicopathological factors and outcomes. The gene discussed is INHBA; the disease is gastric cancer.